Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial - Wikidata - wikimedia - TriplyDB

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial

http://www.wikidata.org/entity/Q33646630

about

Lipids, blood pressure and kidney update 2015 A Randomized Trial of Intensive versus Standard Blood-Pressure Control PURLs: "Go low" or say "No" to aggressive systolic BP goals?The 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of Hypertension Optimizing Medical Management in Patients with Sight-Threatening Diabetic Retinopathy.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SB Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells.Blood glucose screening rates among Minnesota adults with hypertension, Behavioral Risk Factor Surveillance System, 2011.Health outcomes in diabetics measured with Minnesota Community Measurement quality metrics.Type 2 diabetes in Brazil: epidemiology and management.HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis SPRINT Trial Results: Latest News in Hypertension Management.Blood Pressure-Related Outcomes in a Diabetic Population.Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups: Age <50 Years, Diabetes Mellitus, or a History of Stroke What should the target blood pressure goals be?Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy 7th Brazilian Guideline of Arterial Hypertension: Chapter 5 - Therapeutic Decision and Targets Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial.The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes.Glucose targets for preventing diabetic kidney disease and its progression.Hypertension up to date: SPRINT to SPYRAL.Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis.BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME.Management of Hypertension in Patients with Chronic Kidney Disease.Cardiovascular disease prevention strategies for type 2 diabetes mellitus.Synergistic association of combined glycemic and blood pressure level with risk of complications in US veterans with diabetes.Facility-level variation in diabetes and blood pressure control in patients with diabetes: Findings from the Veterans Affairs national database.Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial.Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations : A joint scientific statement from the Austrian Society of Cardiology and the Austrian Society of Hypertension.What should the blood pressure treatment goal be in adults with hypertension in 2016?Patient-centered Blood Pressure: Thresholds, Targets, and Tools in Diabetes.Intensive lowering of blood pressure: Should we SPRINT?Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? A Protagonist View From the SPRINT Trial (Systolic Blood Pressure Intervention Trial).Adequacy of control of cardiovascular risk factors in ambulatory patients with type 2 diabetes attending diabetes out-patients clinic at a county hospital, Kenya.Diabetes: Blood pressure goals in T2DM - time for a rethink?Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort.Hypertension Across a Woman's Life Cycle.Managing Hypertension in the Elderly: What is Different, What is the Same?Combined effect of glycemic and blood pressure control on diabetic retinopathy among Chinese with type-2 diabetes mellitus

P2860

Q26771550-2188675B-273C-4F47-842E-94CB2D7A4EC8 Q27231406-41979A13-360D-4A8F-A89C-46D9C041E25D Q28078922-FF808ED6-E28A-42A2-8138-15C08470989F Q33729817-8B9AA913-D4CE-4F01-A484-4C3F9419F953 Q33740088-E7B0CE30-A63A-48F4-A696-04019694997A Q33908782-CD92D470-D139-4A63-981C-3C85BDDCFD60 Q34583696-074E06D0-6F2E-4C50-9543-F91EE74A708A Q34584279-C6724A14-ADD6-49D4-A8AC-90E107B08731 Q34758108-E3C4DD9E-F2FF-4340-99D0-BF5ABCF0719E Q34982412-E8EEA4A4-D7D5-4928-9C50-42A27034AC38 Q35782729-7F566151-BE59-4A9D-8DF1-A718E877127F Q36623166-1566E040-F77C-49FD-864F-F7775B4C0FFF Q36989451-7BD97F77-B15E-48C1-9353-18C3E70A9FDE Q37240728-882130F2-20A1-4DF6-A24A-A5E3CBCAF0A1 Q37412697-BE1F80F2-F660-4B88-ACF5-28700C5E287A Q37569809-2F947E5B-89BF-438C-A46E-F54CA827BB57 Q37656167-5696F57B-C320-436D-ABF6-4640DE7705B8 Q38378739-3E696C01-8194-446D-9CD2-043760EEA52A Q38602464-1740A128-BBF8-467D-9B8C-E3267F120AA6 Q38736800-9B8093EB-D01E-491B-8D9A-3FA61C50FA32 Q38741216-50C41CD2-927D-432D-8CB2-FE1E1FC4387C Q38753415-682335E8-6C8C-45C7-8F1B-66F3641CF55A Q38827356-48ABDCAF-8340-4144-BADC-AB0212C7BECD Q39096331-90AE8F08-5946-48BC-9357-87005A093C08 Q39268835-D1CAD195-D404-4857-ACB9-B19DA6B51A74 Q39420208-17FE6E9D-8D1C-41B0-A5E0-237F467129B7 Q39958676-4F9AD84C-E406-4F25-8050-6B1A33D5F9DE Q40070444-11CAB814-813E-4E65-8918-853B757DE549 Q40088817-0954D8B5-0849-47EB-9966-A02D7DC967BA Q40711617-01F8A25A-6ACC-4781-95CF-755203DC69B6 Q42332669-A3614CB5-9624-40F8-B06A-AE00A93DCE44 Q42372590-23AF0ECC-3C1C-44F2-B91C-223E52998564 Q42385561-D6EDFEE8-CE36-4D4A-9051-7D3991C85383 Q42727417-01E0890F-44B0-40DC-B4DF-7CBD24EF9CA3 Q47163277-992BA9B2-14E7-4997-89D6-570B2E96EFFE Q47396162-63ECFABF-A2F6-4669-8ED1-8DA61E04C12D Q48199007-494A1CA7-BB8A-457F-8BB3-DE327D2E8ABF Q52577307-C963F0CE-C48A-4031-93E9-37F6F913C29D Q53710215-13792F7A-7AFD-4116-A1AD-4B6DB7C03115 Q57298626-CF4F5454-0F81-4653-919C-7EAA0989742B

P2860

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial

http://www.wikidata.org/entity/Q33646630

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Outcomes of combined cardiovas ...... s: the ACCORD randomized trial

@ast

Outcomes of combined cardiovas ...... s: the ACCORD randomized trial

@en

type

label

Outcomes of combined cardiovas ...... s: the ACCORD randomized trial

@ast

Outcomes of combined cardiovas ...... s: the ACCORD randomized trial

@en

prefLabel

Outcomes of combined cardiovas ...... s: the ACCORD randomized trial

@ast

Outcomes of combined cardiovas ...... s: the ACCORD randomized trial

@en

P1433

Q33646630-50444287-024C-48F8-A8E6-B78E8F7B3F3E

P1476

Q33646630-FE8CE01C-4085-4D3C-8CA3-A30D5698977C

P2093

Q33646630-292C73D2-3191-47EE-95D6-217456805E78

Q33646630-48933DFE-5B12-4BB4-8AA4-D91AAF23F04C

Q33646630-52AD9789-273F-4FAB-BA07-375F2556AF32

Q33646630-5DEEA30F-8C16-4336-97DD-0368D1C35405

Q33646630-87055A6A-910A-4FAD-BDE3-CD7C1C5CC92C

Q33646630-8A6BD807-64A7-454A-B72E-3AF5CEC4CA48

Q33646630-BF6D8137-335D-4E54-B51D-B41CB860414A

Q33646630-CC14016A-F50A-4CF7-914F-816F521815DF

Q33646630-D39B001C-A82A-4132-B1BE-1B8AD9F32FB9

Q33646630-E2C02399-E942-4A33-96DC-2B6F62F4C4CF

P2860

Q33646630-0CDCCA84-306C-45C4-AFD8-8C274690025C

Q33646630-1539EFD7-4585-4A7B-B1A6-13250F19AA3B

Q33646630-1E41FB87-620A-4D2B-B852-29319148BA62

Q33646630-308E2732-64E9-47BB-8799-A21B95F8367C

Q33646630-508F2023-365B-4514-9149-F277927B7359

Q33646630-53642E3F-446D-4C3E-82D8-A80B058AFB26

Q33646630-592E87C5-DD3A-46EE-8AE7-905AB9E9FF51

Q33646630-77B8D0CD-C9F4-4DCA-923E-1624D50DAC9F

Q33646630-7892FCF4-7BDA-4043-8B69-04697003F56B

Q33646630-799215FC-B0F0-4412-810E-538435A70A2C

P304

Q33646630-BEEC04EA-FD71-40FD-9141-1BF9C934EE43

P31

Q33646630-07DE2EE2-F205-4702-95AC-9A5F644FCA7F

P356

Q33646630-6AF7F558-68C0-483F-9F26-9B2444C1D6F0

P407

Q33646630-C51656D6-65E7-411D-84DC-268AFE9F4F8E

P433

Q33646630-E654BBAD-3469-4124-A66A-711F27405911

P478

Q33646630-FE3A6833-4663-4AB8-B1FA-98CEB6269A00

P50

Q33646630-14044DB1-5296-406E-A0EA-B94C24757FD3

Q33646630-18BC3AE5-B3F1-448E-9E9B-30FBEAAC5533

Q33646630-25C09E1D-D45C-45A7-BF34-5C06B8B0DBD2

Q33646630-B3486B09-9916-421C-A622-4757114E5DB5

P577

Q33646630-65815EC8-5897-463B-8DE0-C827309CBB53

P5875

Q33646630-651759D6-613D-4A3E-9C7A-980F1F5837FA

P698

Q33646630-E9A6B6D0-79E2-4E73-BA82-999215D4F759

P921

Q33646630-44C3664A-C550-4D20-A429-0418DC4CE5EA

Q33646630-A2B7DD77-C5AD-4466-9871-8FF613FD06C2

Q33646630-A4AA3673-6A59-473E-82EC-48F71EA8AD50

P932

Q33646630-667C9B15-187D-46A2-9E6C-1356A1BD58D1

P356

P1433

P1476

Outcomes of combined cardiovas ...... s: the ACCORD randomized trial

@en

P2093

Ajay Sood

http://www.w3.org/2001/XMLSchema#string

David C Goff

http://www.w3.org/2001/XMLSchema#string

Edward W Lipkin

http://www.w3.org/2001/XMLSchema#string

Gregory W Evans

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Cutler

http://www.w3.org/2001/XMLSchema#string

K M Venkat Narayan

http://www.w3.org/2001/XMLSchema#string

Matthew C Riddle

http://www.w3.org/2001/XMLSchema#string

Richard H Grimm

http://www.w3.org/2001/XMLSchema#string

Robert M Cohen

http://www.w3.org/2001/XMLSchema#string

Timothy M Morgan

http://www.w3.org/2001/XMLSchema#string

P2860

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

10-year follow-up of intensive glucose control in type 2 diabetes

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

Long-term effects of intensive glucose lowering on cardiovascular outcomes.

Effects of combination lipid therapy in type 2 diabetes mellitus.

Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

P304

1721-1728

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC13-2334

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Hertzel C. Gerstein

Karen L. Margolis

P577

2014-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260527851

http://www.w3.org/2001/XMLSchema#string

P698

24595629

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

type-2 diabetes

P932

4030092

http://www.w3.org/2001/XMLSchema#string